Table 3.
Total cohort (n = 160) | Survivors (n = 103) | Deaths (n = 57) | P value | |
---|---|---|---|---|
Demographic variables |
|
|
|
|
Gender (female) |
81 (50.6) |
58 (56.3) |
23 (40.4) |
0.053 |
Age |
63 (51 to 74) |
62 (51 to 73) |
68 (52 to 75) |
0.026 |
Underlying diseases |
|
|
|
|
Diabetes |
35 (21.9) |
23 (22.3) |
12 (21.1) |
0.852 |
Cirrhosis |
6 (3.8) |
1 (1) |
5 (8.8) |
0.022 |
ESRD |
12 (7.5) |
7 (6.8) |
5 (8.8) |
0.756 |
Immunosuppression |
20 (12.5) |
11 (10.7) |
9 (15.8) |
0.349 |
Cancer |
20 (12.5) |
7 (6.8) |
13 (22.8) |
0.003 |
Chronic cardiac insufficiency |
11 (6.9) |
6 (5.8) |
5 (8.8) |
0.523 |
COPD |
22 (13.8) |
14 (13.6) |
8 (14) |
0.938 |
SIRS |
|
|
|
|
Two SIRS criteria |
41 (25.6) |
28 (27.2) |
13 (22.8) |
0.055 |
Three SIRS criteria |
57 (35.6) |
42 (40.8) |
15 (26.3) |
|
four SIRS criteria |
62 (38.8) |
33 (32) |
29 (50.9) |
|
Severity scores |
|
|
|
|
APACHE II |
17 (12 to 24) |
16 (12 to 20) |
22 (15 to 27) |
<0.001 |
SOFA |
7 (4 to 11) |
6 (3 to 9) |
9 (6 to 12) |
<0.001 |
Laboratory parametersa |
|
|
|
|
Leukocytes day 1 |
13,130 (10,185) |
13,100 (9,490) |
13,160 (12,615) |
0.846 |
Leukocytes day 2 |
14,700 (8,650) |
13,640 (8,290) |
17,265 (8,343) |
0.014 |
Eosinophils day 1 |
55.6 (11.2) |
48.34 (9.55) |
68.92 (26.51) |
0.061 |
Eosinophils day 2 |
91.1 (15.6) |
81.56 (13.04) |
110 (38.99) |
0.777 |
CRP day 1 |
26.56 (21.91) |
27.95 (21.45) |
23.44 (22.67) |
0.460 |
CRP day 2 |
28.85 (19.66) |
28.14 (18.10) |
31.31 (20.46) |
0.377 |
PCT day 1 |
7.81 (34.91) |
6.98 (31.44) |
8.93 (40.28) |
0.325 |
PCT day 2 |
4.82 (20.56) |
4.06 (17.79) |
6.69 (26.12) |
0.058 |
cf-DNA day 1 |
5,265 (5,377) |
5,060 (4,760) |
6,290 (6,405) |
0.730 |
cf-DNA day 2 |
4,375 (5,522) |
4,480 (6,030) |
5,460 (4,580) |
0.287 |
cf-DNA day 1, without ARFb |
5,050 (5,130) |
5,055 (4,562) |
5,580 (6,825) |
0.812 |
cf-DNA day 2, without ARFb | 4,960 (5,410) | 4,980 (5,885) | 4,570 (5,090) | 0.899 |
Data presented as n (%) or median (interquartile range). APACHE, Acute Physiology and Chronic Health Evaluation; ARF, acute renal failure; cf-DNA, cell-free DNA; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ESRD, end-stage renal disease; PCT, procalcitonin; SIRS, systemic inflammatory response syndrome; SOFA, Sequential Organ Failure Assessment. aFor comparison, nonparametric tests were used. bARF defined as renal SOFA ≥3 (n = 34).